JACC Global

American College of Cardiology
  • 0.0(0개의 평가)
  • 의학

Explore cardiovascular science from a global perspective with JACC Global. This podcast highlights original research, regional innovations, and urgent challenges in heart health across diverse healthcare settings worldwide.

  1. 2일 전

    ESC 2026 Special: JACC SimPub Papers You Should Know | JACC Baran

    Hosts Mitsuaki Sawano, MD, Takeshi Kitai, MD, PhD, Kentaro Ejiri, MD, PhD, and Satoshi Shoji, MD, PhD, highlight three JACC papers presented at ESC 2026 and simultaneously published with the meeting. Dr. Kitai discusses new HELIOS-B insights on whether the benefits of vutrisiran in transthyretin amyloidosis with cardiomyopathy are maintained among patients already receiving tafamidis. Dr. Ejiri reviews a nationwide Swedish study of nearly 500,000 heart failure hospitalizations examining how cold spells, heat waves, and non-optimal temperatures influence short-term HF risk, including the different timing of risk after rising versus falling temperatures. Dr. Shoji explores how lepodisiran, an extended-duration siRNA targeting lipoprotein(a), markedly reduces oxidized phospholipids carried by Lp(a), providing further insight into the mechanisms linking Lp(a) with cardiovascular risk. The team discusses what these findings add to current evidence, how they may translate to clinical practice in Japan, and the key questions that remain.

  2. 8월 25일

    The Lancet: OPTIMA-AF, Is 1 Month Enough After PCI? | JACC Baran

    Hosts Mitsuaki Sawano, MD, Shun Kohsaka, MD, Nobuhiro Ikemura, MD, and Satoshi Shoji, MD, welcome Yohei Sotomi, MD, PhD (The University of Osaka), and Ken Kozuma, MD, PhD (Teikyo University) for a special episode made possible through the JACC–Lancet partnership to discuss the OPTIMA-AF trial, published in The Lancet. In this investigator-initiated, multicenter randomized trial of 1,079 patients with atrial fibrillation undergoing PCI, 1 month of DOAC plus a P2Y12 inhibitor followed by DOAC monotherapy was compared with 12 months of dual antithrombotic therapy. The 1-month strategy met the prespecified noninferiority criterion for death or thromboembolic events and reduced major or clinically relevant non-major bleeding from 8.8% to 4.5%. The episode explores whether antithrombotic therapy after PCI can safely be shortened, how intracoronary imaging and contemporary PCI may influence this balance, and how the findings should be interpreted in clinical practice. Drs. Sotomi and Kozuma also take us behind the scenes of OPTIMA-AF, from an ambitious idea born through a research competition among Osaka University-affiliated hospitals, through COVID-related enrollment challenges and a prolonged recruitment period, to an initial rejection, appeal, extensive revision, and eventual publication in The Lancet.

  3. 8월 18일

    HFpEF: Why Earlier May Be Better | JACC Baran

    Hosts Mitsuaki Sawano, MD, Nobuhiro Ikemura, MD, and Satoshi Shoji, MD welcome Shunichi Doi, MD (St. Marianna University School of Medicine) to discuss his JACC: Heart Failure study, Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II. In this prespecified subanalysis of the REDUCE LAP-HF II trial, 522 patients with HFpEF or HFmrEF were categorized by time since heart failure diagnosis (3 years). Longer disease duration was associated with progressive left and right ventricular dysfunction, biatrial remodeling, worsening resting and exercise hemodynamics, and higher rates of heart failure events. In contrast, patients with more recent diagnoses often had normal resting filling pressures with congestion evident only during exercise, suggesting that early HFpEF may be missed by conventional evaluation. The discussion explores whether HFpEF phenotypes represent distinct disease entities or sequential stages of progression, why exercise hemodynamic testing may be critical for early diagnosis, and how identifying HFpEF before advanced remodeling develops may open opportunities for earlier intervention.

    HFpEF: Why Earlier May Be Better | JACC Baran

  4. 8월 11일

    Post-PCI Hematoma: What IVUS Tells Us | JACC Baran

    Percutaneous coronary intervention (PCI) is safer than ever, yet coronary hematoma remains an underrecognized cause of early ischemic complications. In this episode, Host Mitsuaki Sawano, MD welcome Takunori Tsukui, MD and Akiko Maehara, MD to discuss their JACC: Cardiovascular Interventions study comparing 22 event-causing hematomas with 80 event-free hematomas identified from more than 3,000 IVUS-guided PCI procedures. The conversation explores how IVUS can distinguish high-risk from low-risk post-PCI hematomas, the imaging features associated with progression, and how these findings may help operators decide when additional stenting is necessary—and when careful observation may be the better strategy.

    Post-PCI Hematoma: What IVUS Tells Us | JACC Baran

  5. 8월 4일

    Pediatric Heart Transplantation: When Priority Doesn't Match Urgency | JACC Baran

    Pediatric heart transplantation is one of medicine's scarcest resources, where every allocation decision can mean the difference between life and death. But does the current system truly prioritize the children at greatest risk? Hosts Mitsuaki Sawano, MD, and Satoshi Shoji, MD welcome Kazunari Sasaki, MD (Stanford University) to discuss his JACC study, Status Exceptions and Misalignment of Medical Urgency in U.S. Pediatric Heart Transplantation. Using the national OPTN registry of more than 6,000 children awaiting heart transplantation, the study examines whether "status exceptions"—special requests to elevate transplant priority—accurately reflect medical urgency and whether the National Heart Review Board has improved the fairness of organ allocation. The episode explores why well-intentioned exception requests may unintentionally disadvantage the sickest children, how waiting-list mortality varies dramatically within the highest priority category, and why objective measures of medical urgency may be needed to improve equity in donor heart allocation. Dr. Sasaki also shares insights into the evolution of the U.S. transplant system, emerging innovations such as ex vivo heart perfusion, and how data-driven policy can shape the future of pediatric transplantation.

    Pediatric Heart Transplantation: When Priority Doesn't Match Urgency | JACC Baran

  6. 7월 28일

    PACs: Benign Bystanders or AF in Disguise? | JACC Baran

    Premature atrial complexes (PACs) are among the most common arrhythmias encountered in daily practice and are often dismissed as benign. But are they truly harmless—or could some represent the earliest stage of atrial fibrillation (AF)? Hosts Mitsuaki Sawano, MD, and Hiroyuki Sato, MD welcome Satoshi Higuchi, MD (Tokyo Women's Medical University) to discuss his JACC: Clinical Electrophysiology study, Atrial Effective Refractory Periods in Patients With Frequent Premature Atrial Complexes: Implications for Atrial Fibrillation. Building on translational work from experimental models, the study compares atrial effective refractory periods (AERP) in patients with frequent PACs, paroxysmal AF, and persistent AF to better define the electrophysiologic substrate underlying these conditions. The episode explores how electrical remodeling differs between PACs and AF, why pulmonary vein AERP shortens before more diffuse atrial remodeling develops, and what these findings reveal about the progression from atrial ectopy to sustained arrhythmia. The discussion also examines the emerging concept of PAC-induced atrial cardiomyopathy, the challenge of distinguishing "benign" from potentially malignant PACs, and the future of risk stratification and preventive intervention before AF becomes established.

    PACs: Benign Bystanders or AF in Disguise? | JACC Baran

  7. 7월 21일

    Cancer VTE + DOAC: Who Will Bleed? | JACC Baran

    Patients with active cancer face a difficult balance: preventing recurrent venous thromboembolism while avoiding major bleeding during anticoagulation. But which patients are truly at highest bleeding risk? Hosts Mitsuaki Sawano, MD welcome Tomoyuki Nagai, MD (Kyoto Prefectural University of Medicine) and Naohiko Nakanishi, MD (Kyoto Prefectural University of Medicine) to discuss their JACC: CardioOncology study introducing the ONCO-DOAC BLEED Score. Using more than 1,100 patients from COMMAND VTE Registry-2 with external validation in two independent cohorts, the investigators identified eight readily available clinical factors that stratify bleeding risk during DOAC therapy in patients with cancer-associated VTE. The conversation explores why existing bleeding scores fall short in patients with active cancer, how cancer type and disease stage influence bleeding risk, the challenges of developing and validating a practical bedside risk score, and what clinicians should consider when balancing thrombosis prevention against bleeding in everyday practice.

    Cancer VTE + DOAC: Who Will Bleed? | JACC Baran

  8. 7월 14일

    HFpEF Without Obesity: What Coronary Microcirculation Tells Us | JACC Baran

    Host Mitsuaki Sawano, MD, welcomes Kai Nogami, MD (Mayo Clinic), to discuss his JACC Brief Report, "Higher Prevalence of Coronary Microvascular Dysfunction in Patients With HFpEF Without Obesity." Why do some patients develop HFpEF despite not being obese? In this episode, Dr. Nogami explains how combining invasive coronary function testing with exercise hemodynamics revealed a remarkably high prevalence of coronary microvascular dysfunction (CMD) in patients with non-obese HFpEF. The discussion explores why CMD may be a key driver of this distinct HFpEF phenotype, what these findings could mean for Japanese and other Asian populations, and how Mayo Clinic's unique invasive physiology platform provided new insights into HFpEF pathophysiology. Dr. Nogami also shares lessons from transforming the work into a JACC Brief Report and reflects on the enduring legacy of his mentor, the late Dr. Amir Lerman.

    HFpEF Without Obesity: What Coronary Microcirculation Tells Us | JACC Baran
모두 보기(83개)

소개

Explore cardiovascular science from a global perspective with JACC Global. This podcast highlights original research, regional innovations, and urgent challenges in heart health across diverse healthcare settings worldwide.

정보

  • 제작진
    American College of Cardiology
  • 방송 연도
    2025년 - 2026년
  • 에피소드
    83
  • 등급
    전체 연령 사용가
  • 저작권
    © American College of Cardiology Foundation. All rights reserved.
  • 웹사이트 보기
    JACC Global

좋아할 만한 다른 항목